Metraipolis › archive › dc_eb3b58baa7cc

Metastatic Tumour Burden as Prognostic Factor in Nivolumab-Treated Metastatic Renal Cell Carcinoma: An Exploratory Study — Europe PMC PMID:42346220

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42346220
DOI
10.3390/curroncol33060320
License (as archived)
solo-consultazione
Archived
2026-11-01T05:12:31.164Z
SHA-256 of the archived text
c4c86fdf2c5ed4105e82199ea96db2b56fdb96ddef1c162ae6725de8c1ef6276
Stable URL of this page
https://metraipolis.com/documento/dc_eb3b58baa7cc

How to cite

Metastatic Tumour Burden as Prognostic Factor in Nivolumab-Treated Metastatic Renal Cell Carcinoma: An Exploratory Study — Europe PMC PMID:42346220 — Europe PMC (en), https://europepmc.org/article/MED/42346220 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eb3b58baa7cc (Metraipolis archive dc_eb3b58baa7cc, sha256 c4c86fdf2c5ed4105e82199ea96db2b56fdb96ddef1c162ae6725de8c1ef6276)
BibTeX
@misc{dceb3b58baa7cc,
  title = {Metastatic Tumour Burden as Prognostic Factor in Nivolumab-Treated Metastatic Renal Cell Carcinoma: An Exploratory Study — Europe PMC PMID:42346220},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42346220},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eb3b58baa7cc; sha256 c4c86fdf2c5ed4105e82199ea96db2b56fdb96ddef1c162ae6725de8c1ef6276},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42346220. Agents can read the archived copy with the MCP tool read_document.